New agreement allows use of Controlled Particle Dispersion® technology in multiple fields.
Kurve Technology and Schering-Plough signed a new agreement that expands Schering-Plough’s evaluation of and option for exclusivity rights to Kurve Technology’s Controlled Particle Dispersion® (CPD) platform from a single field to multiple fields of use.
Kurve Technology’s CPD contains six critical-to-function design parameters that enable modification of deposition and droplet characteristics. The result is a flexible intranasal technology platform that can deliver virtually any liquid drug—solution or suspension—regardless of formulation characteristics including viscocity, surface tension, or molecule size, according to the company. CPD enables pharmaceutical companies to deliver topical, systemic, nose-to-brain drugs and vaccines with minimal peripheral deposition to the lungs and stomach.
“We are extremely pleased with Schering-Plough’s continued and expanded interest in our nasal delivery technology platforms,” said Marc Giroux, chairman and CEO of Kurve Technology. “This agreement is another significant step in our efforts of working with pharmaceutical companies to develop the most innovative intranasal drug/device combinations in the industry.”
